MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Product development was the major strategy adopted by these major players to maintain their leadership position in the global POC Molecular Diagnostics Market. Some of the key players in the global POC Molecular Diagnostics Market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Biomerieux SA (France), and Danaher (US). The growing prevalence of infectious diseases, increasing number of CLIA product approvals, and rising government initiatives to support the adoption of POC molecular diagnostics in this region are driving the market growth. In 2018, North America is expected to account for the largest share of the global POC Molecular Diagnostics Market. North America is expected to dominate the POC Molecular Diagnostics Market in 2018 This share can be attributed to the increased preference for CLIA-waived tests for influenza diagnostics and faster turnaround time of POC molecular assay tests. The physician offices segment is expected to hold the largest share of the market. On the basis of end users, the market is broadly segmented into physician offices, hospital EDs and ICUs, research institutes, and other end users. Growth in this market can be attributed to the rising prevalence of influenza and TB and the rising demand for the early diagnosis and detection of these diseases, especially in emerging countries.īased on end user, the physician offices segment is expected to account for largest share of the market in 2018 The respiratory application segment is expected to account for the largest share of the global POC Molecular Diagnostics Market in 2018. On the basis application, the market is broadly segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications (meningococcal meningitis, malaria, herpes simplex virus, Ebola, Zika virus). Such benefits are driving the growth of the RT PCR segment.īased on application, the respiratory segment is expected to account for largest share of the market in 2018 RT-PCR is a highly cost-effective and preferred technology for POC settings that allows for the concurrent monitoring of expression levels of multiple genetic messages. The RT-PCR segment is expected to account for the largest share of the global POC Molecular Diagnostics Market in 2018. On the basis of technology, the market is broadly segmented into RT-PCR, INAAT, and other technologies. RT-PCR technology segment is expected to account for largest share of the market in 2018 As a result, their applications have increased, making them the largest segment. An increasing number of assays and kits in this market have been granted the CLIA-waived status, which defines that the product can be used for decentralized settings or nontraditional laboratories, including physicians' offices, emergency rooms, and health department clinics. The assays & kits segment is expected to hold the largest share of the market in 2018 and is also projected to grow at highest CAGR in the global POC Molecular Diagnostics Market during the forecast period. On the basis of product & service, the market is broadly segmented into assays & kits, instruments/analyzers, software & services. By product, the assays & kits segment is expected to dominate the market in 2018
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |